News Image

Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology

Provided By GlobeNewswire

Last update: Nov 15, 2024

NEW YORK, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that data from an interim analysis of the ongoing Phase 2 open-label ADVANCED-2 trial of TARA-002 in patients with non-muscle invasive bladder cancer (NMIBC) will be featured during a poster session at the upcoming 25th Annual Meeting of the Society of Urologic Oncology (SUO) taking place December 4, 2024 to December 6, 2024, in Dallas, Texas. The presentation will include safety data featured in the abstract published today on the SUO website, as well as updated safety and new efficacy data from approximately 20 enrolled patients, the majority of whom are six-month evaluable.

Read more at globenewswire.com

PROTARA THERAPEUTIC INC

NASDAQ:TARA (9/23/2025, 7:21:18 PM)

After market: 3.69 +0.11 (+3.07%)

3.58

-0.09 (-2.45%)



Find more stocks in the Stock Screener

Follow ChartMill for more